GRAIL Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

MENLO PARK, Calif., Feb. 26, 2025 /PRNewswire/ — GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that it has granted equity awards in the form of restricted stock units (“RSUs”) underlying an aggregate of 108,450 shares of GRAIL’s common stock to 15 recently hired non-executive employees as an inducement material to their acceptance of employment with GRAIL. The employment inducement awards were granted under GRAIL’s Inducement Equity Incentive Plan and related form of restricted stock award agreement in accordance with Nasdaq Listing Rule 5635(c)(4).

The inducement plan is used exclusively for the grant of equity awards to individuals who were not previously employees of GRAIL, or following a bona fide period of non-employment, as an inducement material to such individuals entering into employment with GRAIL, pursuant to Nasdaq Listing Rule 5635(c)(4).

The RSUs vest over an approximately four year period, with 25% of the award vesting Feb. 28, 2026, and on each one year anniversary of those respective dates thereafter, subject to continued employment with GRAIL (or any successor to or subsidiary of the Company) through the vesting dates.

About GRAIL
GRAIL is a healthcare company whose mission is to detect cancer early, when it can be cured. GRAIL is focused on alleviating the global burden of cancer by using the power of next-generation sequencing, population-scale clinical studies, and state-of-the-art machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. GRAIL’s targeted methylation-based platform can support the continuum of care for screening and precision oncology, including multi-cancer early detection in symptomatic patients, risk stratification, minimal residual disease detection, biomarker subtyping, treatment and recurrence monitoring. GRAIL is headquartered in Menlo Park, CA with locations in Washington, D.C., North Carolina, and the United Kingdom.

For more information, visit grail.com.

View original content to download multimedia:https://www.prnewswire.com/news-releases/grail-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-302385398.html

SOURCE GRAIL, Inc.

Staff

Recent Posts

Three Finalists Announced for the 2025 Bloom Burton Award

Recognizing the Year's Most Significant Contributions to Canada's Innovative Healthcare IndustryToronto, Ontario--(Newsfile Corp. - May…

10 minutes ago

Clarivate Enhances OFF-X with Pathway Maps to Accelerate Target Safety Assessments

R&D teams can streamline safety evaluations, reduce risks and enable faster decision-making in drug development…

1 hour ago

Google Cloud and Philips Collaborate to Drive Consumer Marketing Innovation and Transform Digital Asset Management with AI

Google Cloud helps streamline marketing processes, enhancing brand consistency and reducing operational costs AMSTERDAM and…

1 hour ago

Julius Clinical and Peachtree BioResearch Solutions Merge to Form a Fully Integrated Global CRO with Increased CNS Capabilities

ZEIST, Netherlands, May 14, 2025 /PRNewswire/ -- Julius Clinical, a leading full-service Contract Research Organization (CRO)…

1 hour ago

SolarEast Launches Global R290 Heat Pump System to Advance Climate Goals and Energy Efficiency

BEIJING, May 14, 2025 /PRNewswire/ -- SolarEast, a leading manufacturer of air-to-water heat pumps, has…

1 hour ago